Clinical Trial Update: Erdafitinib Monotherapy or in Combination With Cetrelimab in Muscle-invasive Bladder Cancer Patients With Fibroblast Growth Factor Receptor (FGFR ) Gene Alterations [Phase 2]

View source ↗

Summary

A Phase 2 trial is evaluating erdafitinib alone or in combination with cetrelimab for FGFR-altered muscle-invasive bladder cancer, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Muscle-invasive Bladder Cancer

Drugs mentioned

• BALVERSA (erdafitinib)
• Cetrelimab

Snippet

Sponsor: Spanish Oncology Genito-Urinary Group | Conditions: Muscle-invasive Bladder Cancer | Phase 2 | Status: RECRUITING